Cancer treatment has traditionally relied on chemotherapy, a blunt instrument that attacks all rapidly dividing cells, often causing many side effects.
However, new NIH funded research using mRNA technology is showing a smarter way to fight cancer. Messenger RNA (mRNA) vaccines, first used for infectious diseases, are now being assessed as treatments that can train the immune system to attack tumors.
mRNA vaccines work by teaching the body’s cells to make proteins that look like parts of cancer cells. This “training” helps the immune system recognize and attack cancer more effectively. Unlike regular vaccines that prevent diseases, mRNA cancer vaccines are designed to help the body fight existing cancers.
Over 120 clinical trials are studying mRNA vaccines for cancers like melanoma, pancreatic cancer, and glioblastoma. For example, Moderna’s mRNA vaccine combined with Merck’s immunotherapy drug showed promising results in melanoma patients, lowering the risk of the cancer coming back.
This research is very exciting, but it could be slowed or stopped if Kennedy decides to end mRNA research because of his opposition to the technology. Right now, cancer mRNA research is still moving forward, but he has already ended mRNA research for infectious disease prevention.
Chemotherapy is a blunt tool that attacks all fast-growing cells, causing side effects like hair loss, nausea, and fatigue. mRNA vaccines are different because they specifically target cancer cells, helping the immune system fight the disease while leaving healthy cells mostly unharmed.
mRNA vaccines may one day replace or work alongside, or even replace chemotherapy, offering more precise, less harmful cancer treatments. If current trials continue to show positive results (and if research isn’t stopped by Kennedy) these vaccines could become a key part of cancer care, making treatments safer and more effective.
mRNA technology could change the way we treat cancer, offering hope for more targeted and personalized care. The science is promising, but its success depends on continued research.
Let’s hope that Kennedy’s anti-mRNA bias doesn’t lead him to end this promising work before it has a chance to save lives.
I think he will.
